Foetal Growth Restriction in Children with Prothrombotic Risk Factors

Summary

Placental infarction is frequently observed in low birth weight children. To evaluate whether low birth weight in healthy term neonates is associated with foetal inherited prothrombotic risk factors this retrospective study was conducted. Outcome measures were “birth weight in the lowest quartile” and “birth weight in the lowest decile” in singletons with a gestational age of ≥37 weeks.

The analyses were based on 375 Caucasian children screened at the Münster childhood thrombophilia centre with complete data for all prothrombotic risk factors (factor V G1691A, prothrombin G20210A, elevated lipoprotein (a), protein C-, protein S-, antithrombin-deficiency). The proportion of children in the lowest birth weight quartile increased from 23.7% to 30.5% to 48.0% for children with no, only single heterozygous and multiple or homozygous defects respectively. The respective adjusted odds ratios (95% confidence intervals) of thrombophilia for birth weight in the lowest quartile (lowest decile) were 1.53 (0.76-3.08) in carriers of one prothrombotic risk factor and 4.01 (1.48-10.84) in subjects carrying multiple or homozygous defects. We identified foetal thrombophilia as an additional cause of low birth weight.

Keywords

Foetal growth restriction - factor V G1691A - prothrombin G20210A - lipoprotein (a) - protein C - protein S - antithrombin

• References

• 1 Salafia CM, Vintzileos AM, Silberman L, Bantham KF, Vogel CA. Placental pathology of idiopathic intrauterine growth retardation at term. Am J Perinatol 1992; 9: 179-84.
• 2 De Wolf F, Carreras LO, Moerman P, Vermylen J, Van Assche A, Renaer M. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent foetal loss, and lupus anticoagulant. Am J Obstet Gynecol 1982; 142: 829-34.
• 3 Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing JB. Increased frequency of genetic thrombophilia in women with complications of pregnancy [see comments] [published erratum appears in N Engl J Med 1999; 341:384]. N Engl J Med 1999; 340: 9-13.
• 4 Goddijn-Wessel TA, Wouters MG, van de Molen EF, Spujbroek MD, Steegers-Theunissen RP, Blom HJ, Boers GH, Eskes TK. Hyperhomocysteinemia: a risk factor for placental abruption or infarction. Eur J Obstet Gynecol Reprod Biol 1996; 66: 23-9.
• 5 Khong TY, Hague WM. The placenta in maternal hyperhomocysteinemia. Br J Obstet Gynaecol 1999; 106: 273-8.
• 6 Ogasawara M, Sasa H, Kajiura S, Aoki K, Yagami Y. Successful management of congenital protein C deficiency with recurrent pregnancy loss. Int J Gynaecol Obstet 1995; 50: 185-7.
• 7 Berg K, Roland B, Sande H. High Lp(a) lipoprotein level in maternal serum may interfere with placental circulation and cause foetal growth retardation. Clin Genet 1994; 46: 52-6.
• 8 Verspyck E, Le Cam Duchez V, Gravier A, Descargues G, Marpeau L, Borg JY. Small for gestational age infant in association with maternal prothrombin gene variant (nt 20210A). Eur J Obstet Gynaecol Reprod Biol 1999; 83: 143-4.
• 9 Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia: Part 1. Thromb Haemost 1996; 76: 651-62.
• 10 Nowak-Göttl U, Junker R, Hartmeier M, Koch HG, Münchow N, Assmann G, von Eckardstein A. Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation 1999; 100: 743-8.
• 11 Junker R, Koch HG, Auberger K, Münchow N, Ehrenforth S, Nowak-Göttl U. Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia. Arterioscler Thromb Vasc Biol 1999; 19: 2568-72.
• 12 Göpel W, Kim D, Gortner L. Prothrombotic mutations as a risk factor for preterm birth. Lancet 1999; 353: 1411-2.
• 13 Dizon-Townson DS, Meline L, Nelson LM, Varner M, Ward K. Foetal carriers of the factor V Leiden are prone to miscarriage and placental infarction. Am J Obstet Gynecol 1997; 177: 402-5.
• 14 Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 396: 64-7.
• 15 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-03.
• 16 Ehrenforth S, von Depka Prondsinski M, Aygören-Pürsün E, Nowak-Göttl U, Scharrer I, Ganser A. Study of prothrombin gene 20210 GA variant in FV:Q506 carriers in relationship to the presence or absence of juvenile venous thromboembolism. Arterioscler Thromb Vasc Biol 1999; 19: 276-80.
• 17 Lane DA, Manucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahläck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia: Part 2. Thromb Haemost 1996; 76: 824-34.
• 18 Voigt M, Schneider KTM, Jährig K. Analyse des Geburtengutes des Jahr-gangs 1992 der Bundesrepublik Deutschland. Geburtsh u Frauenheilk 1996; 56: 550-8.
• 19 Battaglia FC, Lubchenco LO. A practical classification of newborn infants by weight and gestational age. J Pediatr 1967; 71 (Suppl. 02) 159-63.
• 20 Kramer MS. Determinants of low birth weight: methodological assessment and meta-analysis. Bulletin of the World Health Organization 1987; 65: 663-737.
• 21 Salomon O, Steinberg DM, Zivelin A, Gitel S, Dardik R, Rosenberg N, Berliner S, Inbal A, Many A, Lubetsky A, Varon D, Martinowitz U, Seligsohn U. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999; 19: 511-8.
• 22 van Boven HH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdhury V, Bauer KA, Scharrer I, Conard J, Lane DA. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996; 75: 417-21.
• 23 Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-5.
• 24 Ehrenforth S, Junker R, Koch HG, Kreuz W, Münchow N, Scharrer I, Nowak-Göttl U. Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Eur J Pediatr 1999; 158: 97-104.
• 25 Maser H, Rajab AA, Qaryouti S. Neonatal limb gangrene in a newborn infant associated with renal and adrenal vein thrombosis. J Pediatr 1987; 146: 429-31.
• 26 Valderrama E, Gribetz I, Strauss L. Peripheral gangrene in a newborn infant associated with renal and adrenal vein thrombosis. J Pediatr 1972; 80: 101-3.
• 27 Jaiyesimi F, Effiong CE, Lawson EA. Congenital gangrene of an extremity in a Nigerian neonate. Clin Pediatr 1976; 15: 283-5.
• 28 Hajjar KA, Nachman RL. The role of lipoprotein(a) in atherogenesis and thrombosis. Ann Rev Med 1996; 47: 423-42.
• 29 Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339: 303-5.
• 30 Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM, Furie BC. Anti-fibrinolytic activity of apolipoprotein(a) in vivo: Human apolipopotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med 1995; 1: 256-9.
• 31 Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding and plasminogen activation. Arteriosclerosis 1990; 10: 240-5.
• 32 Harpel PC, Gordon BR, Parker TS. Plasmin catalyses binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989; 86: 3847-51.
• 33 Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibits streptokinase-mediated activation of human plasminogen. Biochemistry 1989; 28: 2370-4.
• 34 Simon DI, Fless GM, Scanu AM, Loscalzo J. Tissue-type plasminogen activator binds to and is inhibited by surface-bound lipoprotein (a) and low density lipoprotein. Biochemistry 1991; 30: 6671-7.
• 35 Ezratty A, Simon DI, Loscalzo J. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry 1993; 32: 4628-33.